These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37216661)

  • 1. Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.
    Cusick MM; Tisdale RL; Chertow GM; Owens DK; Goldhaber-Fiebert JD
    Ann Intern Med; 2023 Jun; 176(6):788-797. PubMed ID: 37216661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.
    Tisdale RL; Cusick MM; Aluri KZ; Handley TJ; Joyner AKC; Salomon JA; Chertow GM; Goldhaber-Fiebert JD; Owens DK
    J Gen Intern Med; 2022 Oct; 37(13):3380-3387. PubMed ID: 35137296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
    Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
    Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States.
    Ishigami J; Padula WV; Grams ME; Chang AR; Jaar B; Gansevoort RT; Bridges JFP; Kovesdy CP; Uchida S; Coresh J; Matsushita K
    Am J Kidney Dis; 2019 Jul; 74(1):23-35. PubMed ID: 30898360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
    Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
    EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
    Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
    BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study.
    Lin E; Chertow GM; Yan B; Malcolm E; Goldhaber-Fiebert JD
    PLoS Med; 2018 Mar; 15(3):e1002532. PubMed ID: 29584720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan.
    Kodera S; Morita H; Nishi H; Takeda N; Ando J; Komuro I
    Circ J; 2022 Nov; 86(12):2021-2028. PubMed ID: 36070962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
    McEwan P; Darlington O; Miller R; McMurray JJV; Wheeler DC; Heerspink HJL; Briggs A; Bergenheim K; Garcia Sanchez JJ
    Clin J Am Soc Nephrol; 2022 Dec; 17(12):1730-1741. PubMed ID: 36323444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.
    Bhatt AS; Vaduganathan M; Claggett BL; Kulac IJ; Anand IS; Desai AS; Fang JC; Hernandez AF; Jhund PS; Kosiborod MN; Sabatine MS; Shah SJ; Vardeny O; McMurray JJV; Solomon SD; Gaziano TA
    J Am Heart Assoc; 2024 Mar; 13(5):e032279. PubMed ID: 38390793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
    Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
    Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
    Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
    Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
    Ferguson TW; Tangri N; Tan Z; James MT; Lavallee BDA; Chartrand CD; McLeod LL; Dart AB; Rigatto C; Komenda PVJ
    Kidney Int; 2017 Jul; 92(1):192-200. PubMed ID: 28433383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.
    Thokala P; Hnynn Si PE; Hernandez Alava M; Sasso A; Schaufler T; Soro M; Fotheringham J
    Pharmacoeconomics; 2023 Apr; 41(4):457-466. PubMed ID: 36735201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.
    McEwan P; Davis JA; Gabb PD; Wheeler DC; Rossing P; Chertow GM; Correa-Rotter R; Tamura K; Barone S; Garcia Sanchez JJ
    Clin Kidney J; 2024 Feb; 17(2):sfae025. PubMed ID: 38389710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of screening for chronic kidney disease using a cumulative eGFR-based statistic.
    Zafarnejad R; Chen Q; Griffin PM
    PLoS One; 2024; 19(3):e0299401. PubMed ID: 38478491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.